BiomX (PHGE)
(Delayed Data from AMEX)
$0.98 USD
+0.04 (4.20%)
Updated Oct 16, 2024 03:56 PM ET
After-Market: $0.94 -0.04 (-4.03%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
BiomX Inc. [PHGE]
Reports for Purchase
Showing records 1 - 20 ( 37 total )
Company: BiomX Inc.
Industry: Unclassified
2Q24 Results; Clinical Development Forges On; Topline Readouts Across Both Pipeline Programs Expected Throughout 2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
1Q24 Results; Phage Trials Remain on Track; BX004 Type C Meeting in Mid-2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
Phage Begins to Put Its Foot Down in DFO; BX211 Focus Piece
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
2023 Results; Newly Streamlined Portfolio Positions Phage Therapy For Success
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
Solidifying Role as Phage Leader; Target Lowered to $2 on Dilution But Excited About Merger
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
A Breath of Fresh Air; BX004 Exhibits Positive Efficacy in CF Phase 1b/2a Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
3Q23 Results; All Eyes On Upcoming CF Readout; Phase 1b/2a Part 2 Data Imminent
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
BX004 Part 2 Patient Dosing Complete; Key CF Data Expected 4Q23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
2Q23 Results; BX004 Part 2 Data in November 2023 Represent Major Driver; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
1Q23 Results; BX004 Stays the Course; Part 2 Results Expected in 3Q23; Target Adjusted to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
2022 Results; All Eyes Remain on BX004; Next Clinical Readout Expected 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
Worth the Wait; Early Phase 1b/2a BX004 Data Impress; Part 2 Results Anticipated 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
First Bacteriophage Conference Takeaways; Field Approaching Significant Inflection Point; Time to Pay Attention
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
3Q22 Results; Almost There on CF Data; Should be Exciting; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
2Q22 Results; CF Remains a Priority With Continued Enrollment and Initial Results in 3Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
Boehringer Ingelheim Maintains Interest in XMarker Discovery Platform
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
Phase 1b/2a Study of BX004 Begins Clinical Evaluation in CF; Data Starting in 3Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
KOL Event Highlights Ongoing Need For CF Infection Treatment; Upcoming Data in CF and AD to Bolster Visibility
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
2021 Results; All Eyes On CF and AD Proof of Concept Clinical Data Readouts in 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BiomX Inc.
Industry: Unclassified
New Year, New Allies; Funding From the Cystic Fibrosis Foundation Supports Imminent Phase 1/2 Launch of BX004
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J